Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and β2- microglobulin

Biochemistry and Cell Biology

Volumn 91, Issue 4, 2013, Pages 214-220

  Zhang, Zhuqing ^a   Chen, Kai ^a   Yan, Longchao ^a   Yang, Ziyi ^a   Zhu, Zhanmeng ^a   Chen, Chunlin ^a   Zeng, Jia ^a   Wei, Wei ^a   Qi, Xia ^a   Ren, Shuangyi ^a   Zuo, Yunfei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

DC SIGNR; expression; Non Hodgkin lymphoma

Indexed keywords

DC-SIGNR; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION; IMMUNOHISTOCHEMISTRY; INTEGRAL MEMBRANE PROTEINS; INTERCELLULAR ADHESION; NON-HODGKIN LYMPHOMA; SIMIAN IMMUNODEFICIENCY VIRUS;

ADHESION; BIOLOGICAL MEMBRANES; CELL ADHESION; ENDOTHELIAL CELLS; LACTIC ACID; MOLECULES; ONCOLOGY; PROTEINS;

BODY FLUIDS;

BETA 2 MICROGLOBULIN; CELL ADHESION MOLECULE; DENDRITIC CELL SPECIFIC INTERCELLULAR ADHESION MOLECULE GRABBING NONINTEGRIN RELATED PROTEIN; LACTATE DEHYDROGENASE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR LYMPHOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; CARBOXYLIC ESTER HYDROLASES; CELL ADHESION; CELL ADHESION MOLECULES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; LECTINS, C-TYPE; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 84880657172     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2012-0110     Document Type: Article

References (54)

1. Abdou A.M. Gao X. Cozen W. Cerhan J.R. Rothman N. Martin M.P. et al. 2010. Human leukocyte antigen (HLA) A1-B8-DR3(8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. Leukemia, 24 (5): 1055-1058. 10.1038/leu.2010.17. 20147981.
2. Alvarez C.P. Lasala F. Carrillo J. Muñiz O. Corbí A.L. Delgado R. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76 (13): 6841-6844. 10.1128/JVI.76.13.6841-6844.2002. 12050398.
3. Ansell S.M. Witzig T.E. Kurtin P.J. Sloan J.A. Jelinek D.F. Howell K.G. et al. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood, 99 (1): 67-74. 10.1182/blood.V99.1.67. 11756154.
4. Bashirova A.A. Geijtenbeek T.B. van Duijnhoven G.C. van Vliet S.J. Eilering J.B. Martin M.P. et al. 2001. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J. Exp. Med. 193 (6): 671-678. 10.1084/jem.193.6.671. 11257134.
5. Bataille R. Durie B.G. Grenier J. 1983. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br. J. Haematol. 55 (3): 439-447. 10.1111/j.1365-2141.1983.tb02158.x. 6357266.
6. Blann A.D. Gurney D. Wadley M. Bareford D. Stonelake P. Lip G.Y. 2001. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis, 12 (1): 43-50. 10.1097/00001721-200101000- 00007. 11229826.
7. Boffetta P.I. 2011. Epidemiology of adult non-Hodgkin lymphoma. Ann. Oncol. 22 (4): 27-31. 10.1093/annonc/mdr167.
8. Boily-Larouche G. Iscache A.L. Zijenah L.S. Humphrey J.H. Mouland A.J. Ward B.J. et al. 2009. Fcunctional genetic variants in DC-SIGNR are associated with mother-to-child transmission of HIV-1. PLoS One, 4 (10): e7211. 10.1371/journal.pone.0007211. 19809496.
9. Bray F. Ren J.S. Masuyer E. Ferlay J. 2013. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer, 132 (5): 1133-1145. 10.1002/ijc.27711. 22752881.
10. Cao Y. Shi Y.X. Chen J.O. Tan Y.T. Cai Y.C. Luo H.Y. et al. 2012. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumor Biol. 33 (4): 1039-1044. 10.1007/s13277-012-0337-z. 22328138.
11. Castronovo V. Campo E. van den Brûle F.A. Claysmith A.P. Cioce V. Liu F.T. et al. 1992. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J. Natl. Cancer Inst. 84 (15): 1161-1169. 10.1093/jnci/84.15.1161. 1386115.
12. Coiffier B. Gisselbrecht C. Vose J.M. Tilly H. Herbrecht R. Bosly A. et al. 1991. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Grouped'Etudes des LymphomesAgressifs. J. Clin. Oncol. 9 (2): 211-219. 1703226.
13. Cresswell P. Springer T. Strominger J.L. Turner M.J. Grey H.M. Kubo R.T. 1974. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc. Natl. Acad. Sci. U.S.A. 71 (5): 2123-2127. 10.1073/pnas.71.5.2123. 4134761.
14. Drake P.M. Cho W. Li B. Prakobphol A. Johansen E. Anderson N.L. et al. 2010. Sweetening the pot: Adding glycosaylation to the biomarker discovery equation. Clin. Chem. 56 (2): 223-236. 10.1373/clinchem.2009.136333. 19959616.
15. Drillenburg P. Pals S.T. 2000. Cell adhesion receptors in lymphoma dissemination. Blood, 95 (6): 1900-1910. 10706853.
16. Dymicka-Piekarska V. Kemona H. 2009. Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thromb. Res. 124 (1): 80-83. 10.1016/j.thromres.2008.11.021. 19136145.
17. Grey H.M. Kubo R.T. Colon S.M. Poulik M.D. Cresswell P. Springer T. et al. 1973. The small subunit of HL-A antigens is beta 2-microglobulin. J. Exp. Med. 138 (6): 1608-1612. 10.1084/jem.138.6.1608. 4128442.
18. Haznedaroglu I.C. Benekli M. Ozcebe O. Savaş M.C. Güllü I.H. Dündar S.V. et al. 2000. Serum L-selectin and P-selectin levels in lymphomas. Haematologia (Budap.), 30 (1): 27-30. 10.1163/15685590051129841. 10841321.
19. Hebbar M. Révillion F. Louchez M.M. Vilain M.O. Fournier C. Bonneterre J. et al. 1998. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin. Cancer Res. 4 (2): 373-380. 9516925.
20. Hoskins P.J. Ng V. Spinelli J.J. Klimo P. Connors J.M. 1991. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J. Clin. Oncol. 9 (2): 220-226. 1703227.
21. Irimura T. Matsushita Y. Sutton R.C. Carralero D. Ohannesian D.W. Cleary K.R. et al. 1991. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res. 51 (1): 387-393. 1988099.
22. Irjala H. Alanen K. Grénman R. Heikkilä P. Joensuu H. Jalkanen S. 2003. Mannose receptor(MR) and common lymphatic endothelial and vascular endothelial receptor(CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63 (15): 4671-4676. 12907648.
23. Iurisci I. Tinari N. Natoli C. Angelucci D. Cianchetti E. Iacobelli S. 2000. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6 (4): 1389-1393. 10778968.
24. Kirn D. Mauch P. Shaffer K. Pinkus G. Shipp M.A. Kaplan W.D. et al. 1993. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J. Clin. Oncol. 11 (7): 1336-1343. 8315431.
25. Konstantinov K.N. Robbins B.A. Liu F.T. 1996. Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Am. J. Pathol. 148 (1): 25-30. 8546213.
26. Kurzrock R. Redman J. Cabanillas F. Jones D. Rothberg J. Talpaz M. 1993. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptom. Cancer Res. 53 (9): 2118-2122. 8481913.
27. Lin G. Simmons G. Pöhlmann S. Baribaud F. Ni H. Leslie G.J. et al. 2003. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77 (2): 1337-1346. 10.1128/JVI.77.2.1337-1346.2003. 12502850.
28. Lis H. Sharon N. 1973. The biochemistry of plants lectins (Phytohemagglutinins). Annu. Rev. Biochem. 42 (0): 541-574. 10.1146/annurev.bi. 42.070173.002545. 4599386.
29. Litam P. Swan F. Cabanillas F. Tucker S.L. McLaughlin P. Hagemeister F.B. et al. 1991. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann. Intern. Med. 114 (10): 855-860. 2014946.
30. Maartense E. Kluin-Nelemans H.C. Noordijk E.M. 2003. Non-Hodgkin's lymphoma in the elderly. A review with emphasis on elderly patients, geriatric assessment, and future perspectives. Ann. Hematol. 82 (11): 661-670. 10.1007/s00277-003-0722-1. 12923662.
31. Marzi A. Gramberg T. Simmons G. Möller P. Rennekamp A.J. Krumbiegel M. et al. 2004. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 78 (21): 12090-12095. 10.1128/JVI.78.21.12090-12095.2004. 15479853.
32. Misonou Y. Shida K. Korekane H. Seki Y. Noura S. Ohue M. et al. 2009. Comprehensive clinic-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. J. Proteome Res. 8 (6): 2990-3005. 10.1021/pr900092r. 19541771.
33. Mitchell D.A. Fadden A.J. Drickamer K. 2001. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem. 276 (31): 28939-28945. 10.1074/jbc.M104565200. 11384997.
34. Novak A.J. Grote D.M. Stenson M. Ziesmer S.C. Witzig T.E. Habermann T.M. et al. 2004. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood, 104 (8): 2247-2253. 10.1182/blood-2004-02-0762. 15251985.
35. O'Hanlon D.M. Fitzsimons H. Lynch J. Tormey S. Malone C. Given H.F. 2002. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur. J. Cancer, 38 (17): 2252-2257. 10.1016/S0959-8049(02)00218-6. 12441261.
36. Op den Brouw M.L. de Jong M.A. Ludwig I.S. van der, Molen R.G. Janssen H.L. Geijtenbeek T.B. et al. 2008. Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. J. Viral Hepat. 15 (9): 675-683. 10.1111/j.1365-2893.2008.00993.x. 18482282.
37. Pinto A. Carbone A. Gloghini A. Marotta G. Volpe R. Zagonel V. 1993. Differential expression of cell adhesion molecules in B-zone small lymphocytic lymphoma and other well-differentiated lymphocytic disorders. Cancer, 72 (3): 894-904. 10.1002/1097-0142(19930801)72:3<894::AID-CNCR2820720339>3.0.CO;2- A. 8334643.
38. Pöhlmann S. Soilleux E.J. Baribaud F. Leslie G.J. Morris L.S. Trowsdale J. et al. 2001. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc. Natl. Acad. Sci. U.S.A. 98 (5): 2670-2675. 10.1073/pnas.051631398. 11226297.
39. Procházka V. Faber E. Raida L. Langová K. Indrák K. Papajík T. 2012. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk. Lymphoma, 53 (7): 1306-1310. 10.3109/10428194.2011.654339. 22263569.
40. Purdue M.P. Lan Q. Martinez-Maza O. Oken M.M. Hocking W. Huang W.Y. et al. 2009. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood, 114 (13): 2730-2732. 10.1182/blood-2009-04-217521. 19638620.
41. Purdue M.P. Lan Q. Bagni R. Hocking W.G. Baris D. Reding D.J. et al. 2011. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res. 71 (14): 4898-4907. 10.1158/0008-5472.CAN- 11-0165. 21632552.
42. xhexasaccharide in human colorectal cancers: A protential marker of malignant transformation in colon. J. Proteome Res. 8 (2): 702-711. 10.1021/pr800740j. 19152289.
43. Roselli M. Mineo T.C. Martini F. Mariotti S. Ambrogi V. Spila A. et al. 2002. Soluble selectin levels in patients with lung cancer. Int. J. Biol. Markers, 17 (1): 56-62. 11936588.
44. Simmons G. Reeves J.D. Grogan C.C. Vandenberghe L.H. Baribaud F. Whitbeck J.C. et al. 2003. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology, 305 (1): 115-123. 10.1006/viro.2002.1730. 12504546.
45. Soilleux E.J. Barten R. Trowsdale J. 2000. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J. Immunol. 165 (6): 2937-2942. 10975799.
46. Swan F. Jr. Velasquez W.S. Tucker S. Redman J.R. Rodriguez M.A. McLaughlin P. et al. 1989. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J. Clin. Oncol. 7 (10): 1518-1527. 2674337.
47. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. 1993. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329 (14): 987-94. 10.1056/NEJM199309303291402. 8141877.
48. The Non-Hodgkin's Lymphoma Classification Project. 1997 a. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89 (11): 3909-3918. 9166827.
49. The Non-Hodgkin's Lymphoma Classification Project. 1997 b. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol. 8 (10): 973-978. 10.1023/A:1008205619617. 9402170.
50. Wang S.S. Slager S.L. Brennan P. Holly E.A. De Sanjose S. Bernstein L. et al. 2007. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 109 (8): 3479-3488. 10.1182/blood-2006-06-031948. 17185468.
51. Westin E.H. Longo D.L. 2004. Lymphoma and myeloma in older patients. Semin. Oncol. 31 (2): 198-205. 10.1053/j.seminoncol.2003.12.030. 15112150.
52. Yang Z.Z. Grote D.M. Ziesmer S.C. Manske M.K. Witzig T.E. Novak A.J. et al. 2011. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood, 118 (10): 2809-2820. 10.1182/blood-2011-03-340885. 21719603.
53. Yasasever V. Tas F. Duranyildiz D. Camlica H. Kurul S. Dalay N. 2000. Serum levels of the soluble adhesion molecules in patients with malignant melanoma. Pathol. Oncol. Res. 6 (1): 42-45. 10.1007/BF03032657. 10749587.
54. Zelensky A.N. Gready J.E. 2005. The C-type lectin-like domain superfamily. FEBS J. 272 (24): 6179-6217. 10.1111/j.1742-4658.2005.05031.x. 16336259.